Latest Information Update: 18 Jun 2001
At a glance
- Originator Fujisawa
- Class Antifungals
- Mechanism of Action Glucan synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 18 Jun 2001 No-Development-Reported for Mycoses in Japan (Unknown route)
- 24 Apr 1996 New profile
- 24 Apr 1996 Preclinical development for Candidiasis in Japan (Unknown route)